Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
W. G. E. Hölzel, R. Beer, W. Deschner, A. Griesmacher & M. M. Müller. (1995) Individual reference ranges of CA 15—3, MCA and CEA in recurrence of breast cancer. Scandinavian Journal of Clinical and Laboratory Investigation 55:sup221, pages 93-101.
Read now
Read now
Articles from other publishers (20)
Md Abedul Haque. 2023. Current Cancer Biomarkers. Current Cancer Biomarkers
195
227
.
Dorit Di Gioia, Irene Blankenburg, Dorothea Nagel, Volker Heinemann & Petra Stieber. (2016) Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3. Clinica Chimica Acta 461, pages 1-7.
Crossref
Crossref
Petra Stieber, Dorothea Nagel, Irene Blankenburg, Volker Heinemann, Michael Untch, Ingo Bauerfeind & Dorit Di Gioia. (2015) Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer—A retrospective analysis of kinetics on 743 breast cancer patients. Clinica Chimica Acta 448, pages 228-231.
Crossref
Crossref
Pier Nuzzo, Alessandra Rubagotti, Francesca Argellati, Antonio Di Meglio, Elisa Zanardi, Linda Zinoli, Paola Comite, Michele Mussap & Francesco Boccardo. (2015) Prognostic Value of Preoperative Serum Levels of Periostin (PN) in Early Breast Cancer (BCa). International Journal of Molecular Sciences 16:8, pages 17181-17192.
Crossref
Crossref
Andrea Nicolini, Paola Ferrari, Franca Fulceri, Angelo Carpi & Giuseppe Rossi. (2015) An individual reference limit for ‘early’ diagnosis of metastatic breast cancer during postoperative follow-up. Biomarkers in Medicine 9:4, pages 307-317.
Crossref
Crossref
Andrea Nicolini, Paola Ferrari & Giuseppe Rossi. 2015. Advances in Cancer Biomarkers. Advances in Cancer Biomarkers
197
225
.
Vandana G. Abramson & Ingrid A. Mayer. (2011) Clinical Utility of Serum Tumor Markers and Circulating Tumor Cell Assays in the Treatment of Breast Cancer. Current Treatment Options in Oncology 12:4, pages 403-411.
Crossref
Crossref
Hyo Song Kim, Yeon Hee Park, Min Jae Park, Myung Hee Chang, Hyun Jung Jun, Kyoung Ha Kim, Jin Seok Ahn, Won Ki Kang, Keunchil Park & Young-Hyuck Im. (2009) Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. Breast Cancer Research and Treatment 118:1, pages 89-97.
Crossref
Crossref
Chenglin Hong, Ruo Yuan, Yaqin Chai & Ying Zhuo. (2009) Ferrocenyl-doped silica nanoparticles as an immobilized affinity support for electrochemical immunoassay of cancer antigen 15-3. Analytica Chimica Acta 633:2, pages 244-249.
Crossref
Crossref
Jian‐Fu LI, Zhi‐Liang JIANG & An‐Ping DENG. (2008) A Rapid and Highly Selective Resonance Scattering Spectral Assay for Trace Carcinoembryonic Antigen. Chinese Journal of Chemistry 26:12, pages 2297-2301.
Crossref
Crossref
Leisha A. Emens & Nancy E. Davidson. (2003) The follow-up of breast cancer. Seminars in Oncology 30:3, pages 338-348.
Crossref
Crossref
K.L Cheung. (2002) Editorial comment on ‘Serum markers in breast cancer management’. European Journal of Cancer 38:9, pages 1165-1166.
Crossref
Crossref
Roberta D'Alessandro, Mario Roselli, Patrizia Ferroni, Sabrina Mariotti, Antonella Spila, Simona Aloe, Maria Daniela Carone, Maria Rosaria Abbolito, Sandro Carlini, Pasquale Perri, Andrea Ricciotti, Claudio Botti, Francesca Conti, Patrizia Vici, Neva Rossi Chiappetta, Francesco Cognetti, Oreste Buonomo & Fiorella Guadagni. (2001) Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer. Breast Cancer Research and Treatment 68:1, pages 9-19.
Crossref
Crossref
J.P.L. Whitlock, A.J. Evans, L. Jackson, S.Y. Chan & J.F.R. Robertson. (2001) Imaging of Metastatic Breast Cancer: Distribution and Radiological Assessment at Presentation. Clinical Oncology 13:3, pages 181-186.
Crossref
Crossref
K.L. Cheung, C.R.L. Graves & J.F.R. Robertson. (2000) Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treatment Reviews 26:2, pages 91-102.
Crossref
Crossref
Marianne Schmid & Hellmut Samonigg. 1999. Mammacarcinom. Mammacarcinom
73
83
.
R. Molina, X. Filella, J. Jo, C. Agusti & A.M. Ballesta. (2018) CA 125 in Biological Fluids. The International Journal of Biological Markers 13:4, pages 224-230.
Crossref
Crossref
R. Molina & M. Gion. (1998) Use of blood tumour markers in the detection of recurrent breast cancer. The Breast 7:4, pages 187-189.
Crossref
Crossref
A. Van Dalen, V. Barak, A. Cremaschi, M. Gion, R. Molina, M. Namer, P. Stieber, C. Sturgeon & R. Einarsson. (2018) The Prognostic Significance of Increasing Marker Levels in Metastatic Breast Cancer Patients with Clinically Complete Remission, Partial Remission or Stable Disease. The International Journal of Biological Markers 13:1, pages 10-15.
Crossref
Crossref
Pierre M. Valdiguié, Eric Rogari, Joël X. Corberand & Bernard Boneu. (1996) The Performance of the Knowledge-Based System VALAB Revisited: An Evaluation after Five Years. cclm 34:4, pages 371-386.
Crossref
Crossref